Priority Review Voucher for Ultragenyx Pharma
Federal Register notice: FDA has announced the issuance of a priority review voucher to Ultragenyx Pharmaceutical for obtaining approval of a rare pediatric disease product — Mepsevii (vestronidase alfa-vjbk), indicated for treating Mucopolysaccharidosis Type VII. To view the notice, click here.